162 related articles for article (PubMed ID: 24648610)
1. Mass spectrometric screening of ovarian cancer with serum glycans.
Kim JH; Park CW; Um D; Baek KH; Jo Y; An H; Kim Y; Kim TJ
Dis Markers; 2014; 2014():634289. PubMed ID: 24648610
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of ovarian tumor classification by improved reproducibility in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of serum glycans.
Park CW; Jo Y; Jo EJ
Anal Biochem; 2013 Dec; 443(1):58-65. PubMed ID: 23969014
[TBL] [Abstract][Full Text] [Related]
3. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
[TBL] [Abstract][Full Text] [Related]
4. [Identification of serum peptide biomarker for ovarian cancer diagnosis by Clin-TOF-II-MS combined with magnetic beads technology].
Xiu L; Li N; Wang WP; Chen F; Yuan GW; Sun YC; Zhang R; Li XG; Zuo J; Li N; Cui W; Wu LY
Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1188-1195. PubMed ID: 34794222
[No Abstract] [Full Text] [Related]
5. Glycomics analysis of serum: a potential new biomarker for ovarian cancer?
Leiserowitz GS; Lebrilla C; Miyamoto S; An HJ; Duong H; Kirmiz C; Li B; Liu H; Lam KS
Int J Gynecol Cancer; 2008; 18(3):470-5. PubMed ID: 17655680
[TBL] [Abstract][Full Text] [Related]
6. Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis.
Li K; Pei Y; Wu Y; Guo Y; Cui W
J Ovarian Res; 2020 Jan; 13(1):6. PubMed ID: 31924227
[TBL] [Abstract][Full Text] [Related]
7. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
8. Use of the serum glycan state to predict ovarian cancer patients' clinical response to chemotherapy treatment.
Zhao R; Lin G; Wang Y; Qin W; Gao T; Han J; Qin R; Pan Y; Sun J; Ren C; Ren S; Xu C
J Proteomics; 2020 Jul; 223():103752. PubMed ID: 32209427
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometric profiling reveals association of N-glycan patterns with epithelial ovarian cancer progression.
Chen H; Deng Z; Huang C; Wu H; Zhao X; Li Y
Tumour Biol; 2017 Jul; 39(7):1010428317716249. PubMed ID: 28681696
[TBL] [Abstract][Full Text] [Related]
10. Comparative profiling of N-glycans isolated from serum samples of ovarian cancer patients and analyzed by microchip electrophoresis.
Mitra I; Alley WR; Goetz JA; Vasseur JA; Novotny MV; Jacobson SC
J Proteome Res; 2013 Oct; 12(10):4490-6. PubMed ID: 23984816
[TBL] [Abstract][Full Text] [Related]
11. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
[TBL] [Abstract][Full Text] [Related]
12. The ascites N-glycome of epithelial ovarian cancer patients.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
[TBL] [Abstract][Full Text] [Related]
13. Serum glycome profiling: a biomarker for diagnosis of ovarian cancer.
Biskup K; Braicu EI; Sehouli J; Fotopoulou C; Tauber R; Berger M; Blanchard V
J Proteome Res; 2013 Sep; 12(9):4056-63. PubMed ID: 23889230
[TBL] [Abstract][Full Text] [Related]
14. Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer.
Lee JH; Kim YH; Kim KH; Cho JY; Woo SM; Yoo BC; Kim SC
Cancer Res Treat; 2018 Jul; 50(3):883-893. PubMed ID: 28934848
[TBL] [Abstract][Full Text] [Related]
15. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC
Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of serum IgG galactosylation assists differential diagnosis of ovarian cancer.
Qian Y; Wang Y; Zhang X; Zhou L; Zhang Z; Xu J; Ruan Y; Ren S; Xu C; Gu J
J Proteome Res; 2013 Sep; 12(9):4046-55. PubMed ID: 23855414
[TBL] [Abstract][Full Text] [Related]
17. Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.
Wu S; Xu K; Chen G; Zhang J; Liu Z; Xie X
Int J Clin Oncol; 2012 Apr; 17(2):89-95. PubMed ID: 21638024
[TBL] [Abstract][Full Text] [Related]
18. [Preliminary study of MALDI-TOF mass spectrometry-based screening of patients with the NSCLC serum-specific peptides].
An J; Tang C; Wang N; Liu Y; Guo W; Li X; Wang Z; He K; Liu X
Zhongguo Fei Ai Za Zhi; 2013 May; 16(5):233-9. PubMed ID: 23676979
[TBL] [Abstract][Full Text] [Related]
19. Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks.
Timms JF; Menon U; Devetyarov D; Tiss A; Camuzeaux S; McCurrie K; Nouretdinov I; Burford B; Smith C; Gentry-Maharaj A; Hallett R; Ford J; Luo Z; Vovk V; Gammerman A; Cramer R; Jacobs I
Cancer Genomics Proteomics; 2011; 8(6):289-305. PubMed ID: 22086897
[TBL] [Abstract][Full Text] [Related]
20. N-glycan MALDI Imaging Mass Spectrometry on Formalin-Fixed Paraffin-Embedded Tissue Enables the Delineation of Ovarian Cancer Tissues.
Everest-Dass AV; Briggs MT; Kaur G; Oehler MK; Hoffmann P; Packer NH
Mol Cell Proteomics; 2016 Sep; 15(9):3003-16. PubMed ID: 27412689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
